Novinky

Update on review of valsartan medicines following detection of impurity in active substance

Assessing potential impact on patients is priority Viac >>

 

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes. Viac >>

 

European Organisation for Specialised Nurses (ESNO) launches switch management guide between similar biological medicines - a guide for nurses

26th June, Brussels, Belgium - Today, ESNO launched an informative guide for the specialised nursing community to facilitate interactions with patients switching from a reference to a biosimilar medicine. Viac >>

 

Prices of Generic Drugs Associated with Numbers of Manufacturers

Low-cost generic drugs have improved outcomes in patients while saving the health care system more than $1 trillion in the past decade. Viac >>

 

Kľúčom k lepšej dostupnosti liečby pre pacientov s chronickými ochoreniami môžu byť biosimilárne lieky.

Európska lieková agentúra (EMA) schvaľuje biosimilárne lieky (biologicky podobné lieky) už od roku 2006. Hoci príchod nových biosimilárnych liekov a ich úspešné používanie v Európskej únii nezadržateľne rastie, Slovensko stále nemá vhodnú legislatívu, ktorá by ich vstup na trh jednoznačne  podporovala. Viac >>

 

Generiká šetria peniaze pacientov, ich spotreba však na Slovensku stále klesá

Klesajúci trend má aj vstup nových generík na trh. Pokiaľ nedôjde k zmene zákona, hrozí  kolaps liekovej politiky. Viac >>

 

Annual Conference: Do not miss the Global Generic, Biosimilar and Value Added Medicines Conference on 13-15 June in Budapest!

The Joint 24th Medicines for Europe and 21st IGBA Annual Conference will bring together 300 experts including medicine manufacturers, stakeholders and governments to evaluate market trends, innovative commercial strategies, challenges for the pharmaceutical sector and new opportunities to improve access to medicines for patients. Viac >>

 

Press Release - SPC manufacturing waiver, Competition policy, Brexit, pharma incentives European Patent Office take centre stage at 14th Legal Affairs Conference

Summary: Today, the complex legal framework for pharmaceuticals was reviewed by authorities, lawyers and industry leaders at the 14th Medicines for Europe Legal Affairs Conference. Among other issues, the conference underlined the importance of the SPC manufacturing waiver to encourage investment in pharmaceutical production and R&D in Europe and to foster high-skill job creation and economic growth. Viac >>

 

«zobraziť 1 z 6 strán»